MedTrace Logo

Product Surveillance Registry- Deep Brain Stimulation for Epilepsy

NCT01521754 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 191

Last updated 2020-12-11

No results posted yet for this study

Summary

The purpose of this observational registry is to evaluate the long-term effectiveness, safety and performance of market-released Medtronic Neuromodulation products for Deep Brain Stimulation (DBS) for the treatment of refractory epilepsy. In addition, healthcare resource use and patient reported outcomes, such as health related quality of life will be assessed.

Conditions

  • Refractory Epilepsy

Sponsors & Collaborators

  • MedtronicNeuro

    lead INDUSTRY

Principal Investigators

  • Paul Boon, MD · Private

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-06
Primary Completion
2019-06-19
Completion
2019-06-19

Countries

  • Austria
  • Belgium
  • Canada
  • Finland
  • Germany
  • Hungary
  • Italy
  • Netherlands
  • Poland
  • Portugal
  • Russia
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01521754 on ClinicalTrials.gov